From Euro report ( Botanix Web page) 6th of Apri 2023
Acknowledging these businesses vary in different ways (business model, disease areas, existing licensing agreements, ex-US approvals, and product portfolios), indicatively the market has paid:
7x to 23x (14x average) 2-year forward Revenues;
and15x to 90x (45x average) 2-year forward EBITDA..
happy to use 10x on Revenue...
Ann: Botanix Appendix 4E & Announcement of Commercial Day Webinar, page-69
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.050(14.3%) |
Mkt cap ! $724.0M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 40.0¢ | 35.5¢ | $6.075M | 15.87M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 287187 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 1920397 | 33 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |